Pulse Biosciences, Inc. (NASDAQ: PLSE) reported Q4 EPS of ($0.51), versus ($0.53) reported last year.

“We are pleased with our accomplishments over the past year in advancing our proprietary CellFX System and look forward to achieving key commercialization milestones in 2019,” said Darrin Uecker, Pulse Biosciences’ President and Chief Executive Officer.

For earnings history and earnings-related data on Pulse Biosciences, Inc. (PLSE) click here.